US Pat. No. 9,174,189

APPARATUS AND METHOD FOR ULTRASOUND TREATMENT FOR BALLAST WATER MANAGEMENT

THE RESEARCH FOUNDATION F...

1. An apparatus for treatment of ballast water, comprising:
(a) a generally cylindrical module having a tubular wall and an open interior along its axis;
(b) a plurality of transducer probes disposed in the wall of said module and extending more than halfway across said module,
each of said probes having a first end and a second end, the second end of one or more probes being offset from the second
end of one or more adjacent probes about the axis, said second end being located within said open interior of said module,
and each of said probes intersecting with a center of said module along said axis;

(c) a power supply for at least one of said transducer probes;
wherein said transducer probes are capable of emitting ultrasonic waves at said second end.

US Pat. No. 9,093,741

COMPACT REPEATERS FOR WIRELESS SENSING

University of South Flori...

1. A repeater for wireless sensing, the repeater comprising:
a base substrate;
a front substrate orthogonal to the base substrate;
a rear substrate orthogonal to the base substrate;
a receive antenna formed on the front substrate configured to receive an interrogation signal transmitted by another device;
a bias network configured to connect the repeater to a sensor and modulate the interrogation signal based upon a parameter
sensed by the sensor;

a frequency multiplier formed on the base substrate, the frequency multiplier being in communication with the receive antenna
and configured to multiply the frequency of the interrogation signal by a multiplication factor; and

a transmit antenna formed on the rear substrate, the transmit antenna being in communication with the frequency multiplier
and configured to retransmit the modulated interrogation signal at a multiplied frequency.

US Pat. No. 9,393,288

METHODS OF TREATING DISEASES ASSOCIATED WITH PPAR?

The University of Vermont...

1. A method for treating a small vessel disease of the brain, comprising
identifying a subject as having a small vessel disease of the brain and chronically administering to the subject having the
small vessel disease of the brain a relaxin or agonist thereof, wherein the subject is not otherwise in need of treatment
with relaxin or agonist thereof in an effective amount to promote outward remodeling of the small vessels of the brain, wherein
the small vessel disease of the brain is due to hypertension and wherein the relaxin or agonist thereof crosses the blood
brain barrier.

US Pat. No. 9,439,577

NON-INVASIVE METHODS FOR DETERMINING CARDIAC OUTPUT

The University of Vermont...

1. A non-invasive method for measuring cardiac output, comprising
administering to a subject a hyperbaric or hypobaric gas and measuring changes in central or peripheral oxygen saturation
with time using pulse oximetry at a peripheral body site representative of central circulation times, wherein time is measured
from the time of administration of the hyperbaric or hypobaric gas to the measurement taken at the peripheral body site.

US Pat. No. 9,403,016

CARDIAC PACEMAKER AND USES THEREOF

The University of Vermont...

1. An implantable device, comprising
a cardiac pacemaker having a housing, a sensor for detecting a heart rate, and a processor in the housing, connected to the
sensor, that is configured to produce an output signal based on detection of a resting heart rate level by the sensor, wherein
the resting heart rate is indicative of a resting patient, the output signal designed to increase the heart rate over the
resting heart rate level wherein the processor is configured to produce the output signal in response to the resting heart
rate in order to stimulate a remodeling of the heart muscle that results in a heart chamber enlargement in the patient.

US Pat. No. 9,260,486

PEPTIDIC ACTIVATORS OF TYPE I CGMP DEPENDENT PROTEIN KINASES AND USES THEREOF

The University of Vermont...

1. An isolated synthetic peptide, wherein the peptide comprises X1X2FFANLX8 (SEQ ID NO: 10), such that X1 and X2 are Ala, and X8 is Lys, and wherein the peptide is 30 amino acids or less in length and wherein the peptide comprises a terminal modification.

US Pat. No. 9,689,819

ELECTRONIC PSYCHROMETER AND/OR HUMIDISTAT WITH LOW TEMPERATURE AND HIGH HUMIDITY CAPABILITY

The University of Vermont...

1. An electronic psychrometer comprising:
a dry temperature sensor;
a wet temperature sensor;
a fan-less evaporator cage surrounding the at least one wet temperature sensor, wherein the evaporator cage comprises pick
dimension P, wherein pick dimension P is the number of carrier crossings per longitudinal inch of the evaporator cage;

a programmable controller;
a computer readable medium, operatively coupled to the programmable controller, wherein the computer readable medium contains:
a set of programmable controller instructions that, if executed by the programmable controller, are operable to determine
relative humidity (RH) with an accuracy of substantially +/?1% RH.

US Pat. No. 9,335,533

ADJUSTABLE TOTAL INTERNAL REFLECTANCE MICROSCOPY (TIRFM) ILLUMINATOR APPARATUS

The University of Vermont...

1. An adjustable total internal reflectance microscopy (TIRFM) illuminator apparatus, the apparatus comprising:
an objective lens wherein the objective lens comprises:
an optical axis,
an outer circumference;
inner circumference
at least one optical fiber, wherein the at least one optical fiber is adaptable to transmit at least one optical excitation
light wavelength through the outer circumference of the objective lens;

at least one fiber axial translator for focusing the at least one optical excitation light wavelength, wherein the at least
one fiber axial translator is mechanically adjustable in at least one-degree-of freedom;

at least one collimating optical element connectable to the at least optical fiber for impinging the at least one optical
excitation light wavelength on to the optical axis wherein the at least one collimating optical element comprises at least
one optical prism adaptable to impinge the at least one optical excitation light wavelength on to the optical axis through
the outer circumference of the objective lens;

wherein the objective lens is adaptable to transmit emission light wavelength through the inner circumference of the objective
lens; and

said TIRFM illuminator apparatus not including a dichroic mirror for impinging the at least one optical excitation light wavelength
on to the optical axis.

US Pat. No. 9,737,720

CARDIAC PACEMAKER AND USES THEREOF

The University of Vermont...

1. A cardiac pacemaker for implantation within a subject, the pacemaker comprising:
a housing;
at least one motion sensor configured to detect movement of the subject and produce output indicative of the movement; and
at least one processor in the housing, the at least one processor being responsive to the output from the sensor and configured
to produce a pacing signal when the output from the at least one motion sensor indicates the subject is at rest, the pacing
signal being configured to increase a heart rate of the subject above a resting heart rate level, wherein the pacing signal
is configured to stimulate remodeling of the subject's heart muscle.

US Pat. No. 9,410,878

PORTABLE ULTRAFINE PARTICLE SIZER (PUPS) APPARATUS

The University of Vermont...

1. A portable particle sizer system for measuring sizes of particles in an aerosol gas sample, the system comprising:
at least one pump for pumping aerosol gas samples through the system, wherein the aerosol gas comprises particles;
at least one proportional valve connectable to the at least one pump;at least one flow meter connectable to the at least one pump for measuring aerosol gas flow through rates set by the at least
one pump and the at least one proportional valve;at least one corona ionizer for ionizing the particles, wherein the at least one corona ionizer comprises:
at least one tungsten needle; and
at least one ground ring electrode; andat least one reverse differential mobility analyzer (rDMA) for determining the particle size distribution based upon electrical
mobility, wherein the rDMA further comprises
at least one flexible printed electrode detector; and
at least one analog-digital-converter for converting ionized charge to a digital signal.
US Pat. No. 9,409,962

METHODS AND COMPOSITIONS FOR EXPRESSING FUNCTIONAL CLASS XIV MYOSIN

University of Vermont and...

1. A method of producing a functional class XIV myosin polypeptide, the method comprising,
co-expressing three or more polynucleotides in a heterologous expression-system cell, wherein the three or more polynucleotides
comprise a class XIV heavy chain polypeptide-encoding polynucleotide, a first myosin light chain polypeptide-encoding polynucleotide,
and a parasite co-chaperone polypeptide-encoding polynucleotide, wherein the three or more polynucleotides are co-expressed
in the cell under conditions suitable to produce a functional class XIV myosin polypeptide comprising the class XIV heavy
chain polypeptide and the first myosin light chain polypeptide.

US Pat. No. 9,326,722

METHODS OF PREDICTING AND MONITORING LABOR

University of Vermont and...

1. A method of determining labor status in a pregnant subject, the method comprising:
receiving, at an electromyography (EMG) recorder, a plurality of signals, each of the plurality of signals comprising an EMG
signal generated by different regions of a subject's uterine wall and measured with a respective one of a plurality of electrode
pairs, each of the electrode pairs positioned on the subject's abdomen in a manner minimizing or eliminating overlap of the
signal of the plurality of signals measured by two or more of the positioned electrode pairs;

detecting three or more uterine muscle contractions, each of the three or more detected uterine muscle contractions associated
with a respective one of the plurality of signals;

calculating a synchronization factor of the three or more uterine muscle contractions based on a ratio of a summed duration
of each of the three or more detected uterine muscle contractions to a total time spanned by the three or more detected uterine
muscle contractions; and

identifying, responsive to the synchronization factor crossing a predetermined threshold, a labor status of the subject.
US Pat. No. 9,925,230

AUGMENTING THE IMMUNE RESPONSE BY PROMOTING CELL DEATH OF IMMUNE CELLS

The University of Vermont...

1. A composition, comprisinga caspase inhibitor, a cancer antigen, and a carrier, wherein the carrier is a nanoparticle.

US Pat. No. 9,907,828

TREATMENTS OF OXIDATIVE STRESS CONDITIONS

The University of Vermont...

1. A method, comprising:
administering, to a subject having pulmonary fibrosis, an inhibitor of GSTP, wherein the inhibitor comprises gamma-glutamyl-S-(benzyl)cysteinyl-R-phenyl
glycine diethyl ester.

US Pat. No. 9,460,634

SYSTEMS FOR AND METHODS OF DIGITAL RECORDING AND REPRODUCTION OF TACTILE DRAWINGS

University of Vermont and...

1. A method for digitizing and reproducing an original tactile feature formed on a first tactile drawing medium, comprising:
moving a stylus over a path on the first tactile drawing medium to form a tactile feature thereon;
digitally recording the path of the moving stylus to generate digital path data, wherein digitally recording the path includes
detecting the path using a receiver adapted to receive signals either reflected from or transmitted by the stylus; and

reproducing the original tactile feature on a second tactile drawing medium operably disposed in a tactile printer, based
on the original digital path data.

US Pat. No. 9,939,449

DIAGNOSTIC AND THERAPEUTIC METHODS AND PRODUCTS RELATED TO ANXIETY DISORDERS

The University of Vermont...

1. A method for diagnosing and treating post traumatic stress disorder (PTSD) in a female human, comprising:a) analyzing pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in a tissue sample collected from a female human;
b) diagnosing PTSD in the female human having elevated tissue PACAP expression levels as compared to a control tissue sample obtained from a subject who does not have PTSD; and
c) administering to the female human diagnosed in (b) a therapeutically effective amount of an antibody that binds specifically to an epitope at the carboxy-terminal end of PACAP.

US Pat. No. 9,634,732

APPARATUS AND METHOD FOR INDUCTIVE POWER TRANSFER ON AN ELECTRIFIED ROADWAY USING A ROTATING SECONDARY INDUCTOR

University of Vermont and...

1. An apparatus for inductive power transfer from an electrified roadway to an electric motor, the apparatus comprising:
a steel belted radial tire;
an insulated electric wire, wherein the insulated electric wire is wrapped around the steel belt to form an in-tire pickup
inductor for inductively transferring power from the electrified roadway; and

a battery pack for providing battery pack power to the electric drive motor;
a controller, wherein the controller determines if there is sufficient inductive power to power the electric motor, and wherein
if the controller determines there is insufficient inductive power, the controller determines if there is sufficient inductive
power and battery pack power to power the electric motor.

US Pat. No. 9,804,377

LOW NUMERICAL APERTURE EXCLUSION IMAGING

University of Vermont and...

1. A low numerical aperture exclusion imaging apparatus having an electromagnetic illumination source for examining a specimen,
wherein the low numerical aperture exclusion imaging apparatus comprises;
an objective lens optically coupled to the electromagnetic illuminated portion of the specimen, for collecting an image created
by the electromagnetic radiation illuminating a portion of the specimen;

an optical blocking plate disposed between the objective lens and the specimen, wherein the optical blocking plate is positioned
to substantially block electromagnetic radiation transmitted through a center portion of the objective lens, and wherein the
optical blocking plate and objective lens are symmetric about a common axis;

wherein the optical blocking plate comprises:
an optical filter disposed substantially concentrically with the optical blocking plate; and
an optically transparent window disposed contiguously around the outer edge of the absorptive optical filter; and
wherein the optically transparent window comprises a single wavelength transmission filter.

US Pat. No. 9,444,049

METHODS FOR FORMING ONE OR MORE CRYSTALLINE LAYERS ON A SUBSTRATE

University of Vermont and...

1. A method for forming a crystalline film of a material, comprising the steps of:
depositing a solution comprising precursor molecules on a substrate including a base film disposed thereon, wherein the base
film is a template crystalline film, the solution having a base critical speed between a convective regime and an LLD regime,
such that a crystalline film is formed;

wherein the solution is deposited at a speed greater than the base critical speed and the crystalline film has a crystal structure
characteristic of a crystalline film formed from the solution at a deposition speed less than the base critical speed.

US Pat. No. 9,634,632

SYSTEM AND METHOD FOR PROCESSING SIGNALS TO ENHANCE AUDIBILITY IN AN MRI ENVIRONMENT

University of Vermont and...

1. A system for processing signals to enhance patient audibility of as plurality of signals in an Magnetic Resonance Imaging
(MRI) environment, each of the plurality of signals having an amplitude and frequency, the frequency, the system comprising:
an acoustic measuring device for measuring sound power levels generated by the MRI;
a principal frequency component identifier for identifying at least one principal frequency measured by the acoustic measuring
device, wherein the at least one principal frequency exceeds a predetermined acoustic power threshold; and

an audio equalizer for controlling the amplitude and frequency of each of the plurality of signals in accordance with the
at least one principal frequency exceeding the predetermined acoustic power threshold.

US Pat. No. 9,403,401

THERMAL ERASER FOR TACTILE DRAWINGS

University of Vermont and...

1. A thermal eraser for erasing a tactile feature from a tactile drawing medium, comprising:
a housing having a tip section and a back section;
a voltage source operably arranged within at least a portion of the back section; and
a thermal-tip assembly that resides in the tip section and that is in electrical contact with the voltage source, the thermal-tip
assembly having a tip and a heating element,

wherein:
the voltage source provides a current to maintain the tip at a tip temperature sufficient to substantially flatten the tactile
feature by the application of heat from the tip to the tactile feature;

the thermal-tip assembly includes a temperature-regulating circuit configured to control a flow of current from the voltage
source to the heating element;

the tip is defined by a thermally conductive cap sized to contain the heating element and the temperature-regulating circuit;
and

the temperature-regulating circuit includes a temperature sensor that senses the tip temperature, wherein the temperature
sensor:

resides within the cap;
measures a temperature within the cap and proximate the tip; and
provides an indication of the measured temperature to the temperature-regulating circuit such that the temperature-regulating
circuit causes the heating element to heat the cap to a temperature in excess of 135° F.

US Pat. No. 9,783,584

METHODS AND COMPOSITIONS FOR EXPRESSING FUNCTIONAL CLASS XIV MYOSIN

University of Vermont and...

1. A method of producing a functional class XIV myosin polypeptide, the method comprising:
co-expressing three or more polynucleotides in a heterologous expression-system cell, wherein the three or more polynucleotides
comprise a class XIV heavy chain polypeptide-encoding polynucleotide, a myosin light chain polypeptide-encoding polynucleotide,
and a parasite co-chaperone polypeptide-encoding polynucleotide, wherein the three or more polynucleotides are co-expressed
in the cell under conditions suitable to produce a functional class XIV myosin polypeptide comprising the class XIV heavy
chain polypeptide and the myosin light chain polypeptide, and wherein the encoded parasite co-chaperone polypeptide comprises
an amino acid sequence set forth as SEQ ID NO: 4 or a functional variant thereof that has an amino acid sequence with at least
75% sequence similarity to SEQ ID NO: 4 or SEQ ID NO: 12 or a functional fragment thereof that has an amino acid sequence
with at least 75% sequence similarity to SEQ ID NO: 12.

US Pat. No. 9,272,275

METHOD AND SYSTEM FOR THE SELECTIVE OXIDATIVE DECARBOXYLATION OF FATTY ACIDS

University of Vermont and...

1. A method of selectively decarboxylating a fatty acid comprising:
providing a fatty acid feedstock and an aqueous solution of hydrogen peroxide, wherein the fatty acid feedstock comprises
fatty acids having a carboxyl group;

generating a water soluble oxidant by a photo-Fenton reaction of the hydrogen peroxide in the presence of light;
contacting the water soluble oxidant with the fatty acid,
wherein the fatty acids are selectively decarboxylated by the water soluble oxidant to remove the carboxyl group from the
fatty acid and a selectively decarboxylated product is produced, wherein the selectively decarboxylated product is a hydrocarbon
corresponding to the non-carboxyl group portion of the fatty acids; and

isolating the selectively decarboxylated product,
wherein a water/oil interface is formed between the water soluble oxidant and the fatty acid feedstock, and wherein the fatty
acids in the fatty acid feedstock are oriented such that the carboxyl groups of the fatty acids at the water/oil interface
prevent contact between the oxidant and non-carboxyl groups of the fatty acid feedstock.

US Pat. No. 10,228,378

DIAGNOSTIC AND THERAPEUTIC METHODS AND PRODUCTS RELATED TO ANXIETY DISORDERS

The University of Vermont...

1. A method for diagnosing an anxiety disorder in a subject, comprising:a. collecting a DNA sample from the subject;
b. analyzing the DNA sample for the presence of a SNP in a PAC1 receptor gene and/or for epigenetic methylation at a first site within a ADCYAP1R1 CpG island;
c. diagnosing the anxiety disorder in the subject having the SNP in the PAC1 receptor gene and/or having elevated levels of epigenetic methylation; and
d. administering a therapeutically effective amount of a PACAP inhibitor or PACAP receptor antagonist.
US Pat. No. 10,087,435

METHODS AND COMPOUNDS FOR REDUCING THREONYL-TRNA SYNTHETASE ACTIVITY

University of Vermont and...

1. A composition comprising a fusion protein that comprises a threonyl-tRNA synthetase (TARS)-activity-inhibiting polypeptide fragment with TARS inhibiting activity wherein the amino acid sequence of the TARS polypeptide fragment is: (1) a TARS N1 domain sequence consisting of amino acids 82-143 of SEQ ID NO: 2, (2) a modified sequence of (1) with at least 98% identity to the amino acid sequence of the TARS N1 domain sequence and capable of binding a Von Hippel Lindau factor (VHL) polypeptide; or (3) the polypeptide set forth as SEQ ID NO: 7.
US Pat. No. 10,143,718

COVALENT INHIBITORS OF DUAL OXIDASE 1 (DUOX 1)

The University of Vermont...

1. A composition, comprising:a peptide comprising a sequence:
S-P-Re-J-L,  (SEQ ID NO: 8)wherein Re is a reactive electrophile and J is G or P.
US Pat. No. 10,052,365

METHODS AND PRODUCTS RELATING TO GSK3? REGULATION

University of Vermont and...

1. A method of reducing activity of GSK3? in a cell, the method comprising:contacting a cell with a composition comprising an isolated GSK3? polypeptide and a carrier, wherein the polypeptide is a full-length GSK3? protein or a fragment of a full-length GSK3? protein and comprises a phosphorylated residue that corresponds to residue Thr390 in a full-length, wild-type, human GSK3? amino acid sequence, or corresponds to residue Ser389 in a full-length, wild-type, mouse GSK3? amino acid sequence, wherein the contacting results in the isolated GSK3? polypeptide in the cell and reduces GSK3? activity in the cell.
US Pat. No. 10,125,358

METHODS AND COMPOUNDS FOR INCREASING THREONYL-TRNA SYNTHETASE ACTIVITY

University of Vermont and...

1. A method of increasing angiogenesis in at least one cell, the method comprising, contacting a plurality of cells with a pharmaceutical composition comprising an effective amount of a TARS-activity-enhancing compound to increase angiogenesis at least one cell of the plurality of cells, wherein the TARS-activity-enhancing compound comprises:(a) a threonyl-tRNA synthetase (TARS) nucleic acid molecule having the sequence of: (i) SEQ ID NO: 1, (ii) a modified SEQ ID NO: 1 that has at least 99% sequence identity to SEQ ID NO: 1, wherein each of (i) and (ii) encodes a TARS-activity-enhancing polypeptide; or
(b) a TARS polypeptide having the sequence of (iv) SEQ ID NO: 2, (v) a modified SEQ ID NO: 2 that has at least 99% sequence identity to SEQ ID NO: 2, wherein each of (iv) and (v), is a TARS activity enhancing polypeptide.
US Pat. No. 10,487,146

OXIDIZED LDL AS A BIOMARKER FOR NEUROLOGICAL COMPLICATIONS OF PREGNANCY

The University of Vermont...

1. A method for treating a subject comprising:administering to a pregnant subject at risk of seizure having elevated levels of oxLDL, a LOX-1 inhibitor, wherein the LOX-1 inhibitor is an antibody or a small molecule, in an effective amount to treat the subject.

US Pat. No. 10,363,254

METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES

University of Vermont and...

1. A method for treating an individual diagnosed with or suspected of having a Cryptosporidium infection or prophylaxis in an individual who is at risk of having a Cryptosporidium infection comprising administering to the individual a composition comprising a therapeutically effective or a prophylactically effective amount of a compound having the following structure:
wherein R4 is selected from the group consisting of hydrogen atom, C1-C9 alkyl group, and haloalkyl groups;
R5 is selected from the group consisting of substituted or unsubstituted benzyl group, substituted or unsubstituted phenyl group, substituted or unsubstituted phenoxy group, and substituted or unsubstituted aniline group.
US Pat. No. 10,175,237

METHODS AND COMPOUNDS FOR DIAGNOSING THREONYL-TRNA SYNTHETASE-ASSOCIATED DISEASES AND CONDITIONS

University of Vermont and...

1. A method for determining a prognosis in a subject diagnosed with a disorder associated with increased threonyl-tRNA synthetase (TARS) activity, the method comprising:(a) obtaining a biological sample from the subject;
(b) measuring a TARS molecule level in the subject's biological sample;
(c) comparing the TARS molecule level of the subject's sample with a control level of the TARS molecule;
(d) correlating levels of the TARS molecule at least 25% greater than the control level with an indication of unfavorable prognosis and levels of the TARS molecule at or below the control level with a favorable prognosis; and
(e) administering to the subject with an indication of unfavorable prognosis a treatment selected from the group consisting of one or more of a medicament, surgery, radiation and chemotherapy
(f) wherein, the disorder is selected from prostate cancer and ovarian cancer.
US Pat. No. 10,456,441

AUGMENTING THE IMMUNE RESPONSE BY PROMOTING CELL DEATH OF IMMUNE CELLS

The University of Vermont...

1. A method for treating cancer in a subject, comprising administering to a subject having cancer a caspase inhibitor and a cancer antigen in an effective amount to treat the cancer.

US Pat. No. 10,412,906

SAP-COLLECTING DEVICES, SYSTEMS AND METHODS FOR SAP-PRODUCING SAPLINGS

University of Vermont and...

1. A sap-collecting system for collecting sap from a plurality of sap-producing saplings having respective stems each having a cut top end, comprising:a plurality of sap-collecting devices operably disposed one each over respective top ends of the stems to form a vacuum-tight seal, each sap-collecting device having an interior and a first access port;
a line system operably connected to the first access ports;
a vacuum system operably connected to the line system, with the vacuum system including collecting tank, wherein the vacuum system is configured to apply a partial vacuum to each of the interiors of the sap-collecting devices so that sap flows from the top ends of the stems, through the corresponding sap-collecting devices and through the line system to the collecting tank; and
wherein the sap-collecting devices each include:
a flexible bag sized to fit over the top end of the corresponding stem;
at least one securing member configured to secure the flexible bag to the corresponding stem portion and to the end cap to form the vacuum-tight seal; and
a spacer configured to space the flexible bag away from the top end of the corresponding stem.

US Pat. No. 10,370,395

CYMANQUINE COMPOUNDS AND DERIVATIVES THEREOF AND USES THEREOF

University of Vermont and...

1. A compound having the formula:where:M is Mn or Re,
L is a neutral, two-electron donor ligand,
R1 is an amine-substituted alkyl group,
R2 is H, (CH2)nCH3, wherein n is 0 to 20, OMe, OEt, OPh, Ph, CHO, COMe, COPh, CH2OH, CO2H, CO2Me, CO2Et, CH2Ph, NH2, NMe2, NEt2, C6H4Me, C6H4OMe, NH2COMe, F, Cl, Br, or I; and
E is a linker moiety connecting the cyclopentadienyl moiety with the chloroquinoline moiety.

US Pat. No. 10,512,652

USE OF CYMANQUINE COMPOUNDS AS ANTIMALARIAL AGENTS

University of Vermont and...

1. A method of treatment of malaria comprising administering to an individual who has been diagnosed with and/or is suffering from malaria comprising administering to the individual a therapeutically effective amount of a composition comprising one of more compounds of the following formula:wherein:M is Mn or Re,
L is a neutral, two-electron donor ligand,
R1 is an amine-substituted alkyl group,
R2 is H, (CH2)nCH3, wherein n is 0 or any integer from 1 to 20, OMe, OEt, OPh, Ph, CHO, COMe, COPh, CH2OH, CO2H, CO2Me, CO2Et, CH2Ph, NH2, NMe2, NEt2, C6H4Me, C6H4OMe, NH2COMe, F, Cl, Br, or I; and
E is a linker moiety connecting the cyclopentadienyl moiety with the chloroquinoline moiety, wherein E is —NH(CH2)n—, —NH(CH2)nNH—, or —NH(CH2)nNH(CH2)— and n is an integer from 1 to 10.
US Pat. No. 10,350,262

MCJ AGONISTS AND USES THEREFOR

University of Vermont and...

1. A method of increasing a chemo-sensitivity of a cancer cell, the method comprising, contacting a cancer cell with one or more exogenous MCJ agonist compounds in an amount effective to increase sensitivity of the cancer cell to one or more chemotherapeutic agents, wherein the exogenous MCJ agonist compound comprises an MCJ molecule and the exogenous MCJ agonist compound further comprises one or more targeting agents.